Results 61 to 70 of about 67,974,619 (226)

Juvenile systemic lupus erythematosus presenting as pancarditis

open access: yesPediatric Rheumatology Online Journal, 2019
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with marked variation in its clinical presentation. Juvenile SLE (jSLE) accounts for 15–20% of all cases and is diagnosed when SLE manifests before 18 years of age. Pancarditis
D. O’Leary   +6 more
doaj   +1 more source

Complement Activation Linked to Type II Interferon Signaling in Still Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans   +115 more
wiley   +1 more source

Review of presentations at the 6th European Lupus Meeting 3-5 March 2005. [PDF]

open access: yes, 2005
The 6th European Lupus Meeting was held at the Royal College of Physicians of London and was attended by 450 delegates. The conference brought together leading speakers from Europe and North America who reviewed current knowledge and exciting new ...
Rahman, A   +3 more
core  

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom   +21 more
wiley   +1 more source

The dynamic relationship of gut microbiota with sex hormones in systemic lupus erythematosus

open access: yes, 2023
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease. The sex hormones estrogen and testosterone may have an influence on the production of antibodies. In addition, the gut microbiota also shows an effect on the onset and progression
Marcel Katrib   +3 more
core   +1 more source

Expert Perspectives: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

open access: yesArthritis &Rheumatology, EarlyView.
Treat‐to‐target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal treat‐to‐target framework for adult IIM has not yet been ...
Shiri Keret   +2 more
wiley   +1 more source

Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients

open access: yesThe Turkish Journal of Gastroenterology, 2021
Objectives: This study aims to examine the frequency and clinical association of lupus-related vasculitis in patients with systemic lupus erythematosus (SLE).
Sherif M Gamal   +5 more
doaj  

Systemic Lupus Erythematosus Presenting as Macrophage Activation Syndrome [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Macrophage Activation Syndrome (MAS), a potentially life threatening condition belongs to acquired cause of Hemophagocytic lymphohistiocytosis (HLH) group of diseases more often found in children than adults.
Satyabrata Guru   +3 more
doaj   +1 more source

Mental disorders in children with rheumatic diseases

open access: yesНаучно-практическая ревматология
The prevalence of concomitant mental disorders in children with rheumatic diseases is notably higher than in the overall population. However, psychiatric comorbidity in pediatric rheumatology remains poorly understood, whereas approaches to mental ...
A. V. Santimov   +2 more
doaj   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy